Having trouble accessing articles? Reset your cache.

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches
FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for migraine.

China approves BioMarin's Vimizim
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said China's National Medical Products Administration (NMPA) approved Vimizim elosulfase

Read the full 516 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE